-
Build a solid line of defense for the grassroots!
Time of Update: 2022-08-15
Donghuayuan Smart Health Cabin solution through the "Internet +" innovative health service platform, with the concept of disease prevention and early treatment, through modern Internet technology, information integrated management platform and a series of professional medical testing equipment, to provide people with Self-service physical examination, establish health records for everyone and update and track management in real time .
-
How attractive is the automatic packaging production line?
Time of Update: 2022-08-15
This time, the automatic cartoning, packing, unpacking and packaging production line displayed at the pharmaceutical machine event is one of the results In this context, Zhejiang Jiade also keeps pace with the times, grasps the trend of packaging automation and intelligence, and continuously improves the automation level of equipment.
-
good news!
Time of Update: 2022-08-15
All products of the company are designed and manufactured according to GMP and FDA standards, and their main technical indicators are at the high level in China Haoming Microwave has always been committed to the development and application of microwave technology and hot air technology in the fields of food, medical treatment, wood, chemical fiber, chemical industry, rubber, ceramics, papermaking, environmental protection, textile and other fields, as well as the production and manufacture of complete sets of equipment.
-
The pharmaceutical company's IPO failed due to unreviewed core products
Time of Update: 2022-08-15
The answer to this question will undoubtedly affect the company's continued profitability In addition to the unreviewed core varieties, the China Securities Regulatory Commission is also concerned about the company's aluminum-magnesium pirin tablets (II) being transferred out of the Sichuan Medical Insurance Catalog.
-
Good news!
Time of Update: 2022-08-15
, as well as general contracting services for industry project construction Since its establishment, Jinzong Enterprise has always been focusing on the research and development, manufacturing and complete production line output of emulsification, dispersion, synthesis reaction, stirring, mixing and grinding equipment for pharmaceuticals, food, cosmetics, chemicals, etc.
-
After investing in the hospital and burning more than 1 billion, the listed company reluctantly "cut the meat" and left the market
Time of Update: 2022-08-12
The listed company Youngor plans to withdraw from the health industry. It announced that it will donate Puji Hospital and related assets to the Ningbo Municipal People's Government. The estimated val
-
Attack the 100 billion market!
Time of Update: 2022-08-12
Data source: Minet database, NMPA On May 23, CDE's official website showed that Qilu Pharmaceutical's Class 1 new drugs QLH11906 tablets and QL1706 injection have obtained the implied license for clinical trials, and are intended to be used for advanced solid tumors and small cell lung cancer .
-
Osaikang fights again PPI improved new drug 3 billion team will add heavy varieties
Time of Update: 2022-08-12
com China's public medical institutions terminal competition pattern As the first echelon of domestic PPI preparations, Osaikang currently has five major products, all of which are injections.
-
Puli's new improved drug, Memantine Hydrochloride Granules, is in full swing!
Time of Update: 2022-08-10
Figure 1: 2021 Memantine Sales Percentage in Various End Markets Source: Mi intranet database The terminals of public medical institutions in China are the main battlefield of Memantine.
-
Mental stress detection new forces!
Time of Update: 2022-08-10
Department personnel experience equipment Donghuayuan heart rate variability detector (mental stress analyzer) expert type is stationed in the medical examination department of the 924th Hospital of the PLA Joint Logistics Support Force, providing fast and effective professional mental health screening services for the medical examination department .
-
Kinglai Group | Helping the transformation of the special medical food industry!
Time of Update: 2022-08-10
; but for special medical food, the quality requirements and products of medicine are closer to Attributes, combined with Kinglai's decades of experience in the pharmaceutical industry, it is easier for everyone to ignore a factor that causes dead ends and affects products - pipeline connection .
-
Renfu Medicine "2.12 billion" sale of assets
Time of Update: 2022-05-25
01Enterprise announcement The content of the announcement shows: In order to focus on the main business and optimize the company's business structure and asset-liability structure, the company and Hongtai Group signed the "Conditional Share Transfer Agreement Regarding the 7.
-
1.3 billion varieties!
Time of Update: 2022-05-25
Sales of nadroparin calcium injection in public medical institutions in China (unit: 10,000 yuan) Source: Minet.
hospital hospital hospital Sales of nadroparin calcium injection in public medical institutions in China (unit: 10,000 yuan) Source: Minet.
-
Overweighting the best-selling anti-virus variety, Sunshine Pharmaceuticals grabs the second domestic company
Time of Update: 2022-05-24
Figure 1: Approval of Oseltamivir Phosphate Dry Suspension Source: NMPA official website Table 1: TOP5 varieties of systemic antiviral drugs in 2021E retail market Source: Minet.
Figure 1: Approval of Oseltamivir Phosphate Dry Suspension Source: NMPA official website Table 1: TOP5 varieties of systemic antiviral drugs in 2021E retail market Source: Minet.
-
Eli Lilly's Oral JAK Inhibitor Olumiant Effective in Severe COVID-19 Patients
Time of Update: 2022-05-24
According to the latest results from the RECOVERY trial, Eli Lilly and Incyte's oral JAK inhibitor Olumiant (Chinese trade name: elemin, generic name: baricitinib, baricitinib) in combination with other drugs in hospitalized severe COVID-19 patients, Reduced the risk of death by 13% .
-
Stellar Pharmaceutical's Levofloxacin Injection Enters the Administrative Approval Stage
Time of Update: 2022-05-24
Like many original products developed by foreign companies, Daiichi Sankyo Pharma actively chose out of the market by quoting high prices in these two centralized procurements .
-
Yangtze River wins the first imitation of super antibiotics
Time of Update: 2022-05-24
At present, more than ten domestic enterprises have deployed levetiracetam tablets for consistency evaluation (including supplementary applications and new classification declarations), including Yangzijiang, Shenghuaxi, Prokangyu, Jingxin Pharmaceutical, Huahai Pharmaceutical, Xinlitai , China Resources Secco, Northeast Pharmaceutical Shenyang First Pharmaceutical, Sihuan Pharmaceutical 9 companies have passed or deemed to have passed the consistency evaluation .
-
Venus-Neo expandable biological stem valve successfully completed the world's first clinical application
Time of Update: 2022-05-23
HK), China’s leading comprehensive platform for innovative devices for structural heart disease, announced that its self-developed new-generation expandable biological stem valve Venus- Neo, recently successfully completed the world's first clinical trial applied to humans (First-in-Man, FIM) at Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology ("Wuhan Union") .
-
HER2 double anti-KN026 combined with chemotherapy for gastric cancer registration clinical trial completed the first patient dosing
Time of Update: 2022-05-23
KN026-001 is a randomized, multicenter, phase II/III clinical study evaluating the efficacy and safety of KN026 combined with chemotherapy in patients with HER2-positive gastric cancer (including gastroesophageal junction adenocarcinoma) who have failed first-line therapy .
-
Phase III clinical study CheckMate -816 confirmed: preoperative use of Opdivo combined with chemotherapy significantly improved event-free survival in patients with non-small cell lung cancer
Time of Update: 2022-05-23
CheckMate -816 is the first phase III clinical study to demonstrate that an immune-based combination therapy can significantly improve EFS and pathological complete response (pCR) rates in patients with non-small cell lung cancer in the neoadjuvant phase .
